We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines.
The following companies have amended their advertising following MHRA…
Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.
Overview Our 2025/26 business plan reaffirms MHRA’s commitment to…
MHRA achievements and highlights for 2025/26 and key projections for 2026/2027.
The minutes of the ministerial annual accountability review of the Medicines and Healthcare products Regulatory Agency (MHRA).
MHRA transactions over £500 made using the government procurement card (GPC).
A programme to help decision making across the lifecycle of products, benefitting both regulatory and health technology assessment (HTA) evaluations.
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
MHRA annual report and accounts 2024 to 2025.
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency's strategic direction over the next three years.
MHRA performance metrics for clinical trials and established medicines assessment.
Progress made in delivering the Patient Involvement Strategy, October 2021 - January 2025.
Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 20 September 2022 and 5 May 2023.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).